Navigation Links
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
Date:9/3/2008

y oxygen deprivation (hypoxia) at the cellular level. Using a novel mechanism of action, TSC enhances the diffusion of oxygen through blood plasma, increasing the rate of oxygen transport and thus treating the symptoms of hypoxia at their source.

In 2007, the Company successfully completed a Phase I safety study of TSC. This randomized, double-blind, placebo-controlled, dose-escalation study in 40 subjects evaluated the tolerability and pharmacokinetics of an intravenous bolus injection of TSC in healthy human subjects. The study demonstrated that TSC is well tolerated, and raised no significant clinical safety issues in humans at doses higher than the doses being used in ongoing clinical trials.

About Multi-Center Trial in Peripheral Arterial Disease Patients:

This randomized, double-blinded, placebo-controlled trial will consist of four cohorts of 12 patients each, to be enrolled sequentially over an escalating range of TSC dosages. Subjects in the study will receive injections of either TSC or placebo intravenously once daily for five consecutive days. Safety and tolerability will be evaluated in a safety review of each cohort before any patients are enrolled into the next cohort. Patients will be evaluated during the study for safety parameters and for clinical endpoints using a treadmill test at prescribed time points. Follow-up assessments will occur at 5, 14 and 30 days after the last dose. The objectives of the study are to evaluate the safety and pharmacokinetics of multiple doses of TSC; establish a dose-response relationship and effect of TSC on peak walking time and claudication onset time in intermittent claudication patients; determine the effect of TSC on potential hypoxia biomarkers; and evaluate the impact of TSC on quality-of-life parameters using the assessments measured in the Walking Impairment Questionnaire routinely used in PAD research. More information on this trial, designated NCT00725881, can be found on the clinicaltr
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Over 200 runners participated in ... Benefit the Radiation Oncology Institute (ROI), hosted by Radiation ... Gate Park in San Francisco.  "Donations ... CEO of Radiation Business Solutions, "but at this ... over $70,000 for the ROI this year. This surpasses ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Systems, Inc. (NASDAQ: DCTH ) announced today that ... agreement for the Delcath Hepatic CHEMOSAT ® Delivery system ... Oncologia ---IEO), a premier European cancer treatment and research center ... the Company will provide the IEO with logistics and clinical ...
... Reportlinker.com announces that a new ... its catalogue: , Frost & ... http://www.reportlinker.com/p0490686/Frost--Sullivan-Speaks-Candidly-with-US-Pharmacists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmacies_and_Drug_Stores ... feedback provided by a healthcare pharmacist ...
Cached Medicine Technology:Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 2Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 3Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union 4Frost & Sullivan Speaks Candidly with U.S. Pharmacists 2Frost & Sullivan Speaks Candidly with U.S. Pharmacists 3
(Date:9/19/2014)... in infertile land, and bear many beans that are ... most legumes have a symbiotic relationship with bacteria, called ... then supply the host plant with ammonia as a ... nodules in their roots. However, if too many root ... of the plants, because the energy cost of maintaining ...
(Date:9/19/2014)... images representing various glosses and then they measured ... They found that a specific population of neurons ... to either the contrast-of-highlight, sharpness-of-highlight, or brightness of ... parameters are used as parameters when the brain ... that different parameters are represented by different populations ...
(Date:9/19/2014)... September 19, 2014 Lifeinsure.biz has ... insurance riders that can be purchased without medical examinations. ... up and make a life insurance policy more advantageous. ... find more about extra options available for a no ... without medical examinations required is simple to purchase, however ...
(Date:9/19/2014)... InventHelp, a leading inventor service company, announces ... has created an accessory designed for use with a stretcher ... transport. This invention is patented. , “Patient ... place until removed, guarding a patient’s head and upper body ... from irritating smoke or rain. The accessory would be pulled ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... Stevie Wonder tickets for his 2014 concert tour. ... In the music business, there are a handful of artists ... Stevie Wonder. Born in Saginaw, MichIgan, Wonder has been a ... During his time in the music business, he has released ...
Breaking Medicine News(10 mins):Health News:Long-distance communication from leaves to roots 2Health News:Neurons express 'gloss' using three perceptual parameters 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:InventHelp® Client Patents “Patient Protector” – Designed to Protect Patients During Transport 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3
... and Mental Hygiene (DOHMH) has banned at least three herbal ... lead and mercury. // , ,"Though there are no ... Institute of Medicine of the National Academies recommends that certain ... million) of lead and no more than 1 ppm of ...
... lose their beauty - they merely move it from their faces ... very normal girl who was in pursuit of her dreams until ... 19th of September 1999 changed her life. She met with a ... was burnt. She lost her ears, nose, left eyelid and most ...
... to the same chromosome regions which are connected with ... which exists between alcohol consumption and smoking may // ... overlap. Environmental factors also contribute towards alcoholism. Drinking and ... the lead author of the study. As many as ...
... Rogers has won the right to fight for receiving the new ... aggressive type of breast cancer and wants to make sure that ... disease is in its early stage has meant that the primary ... already taken legal recourse for the same. Even Patricia Hewitt, the ...
... in South Australia for every 100,000 people, which is reportedly ... at 11. The amount of Government funding to NGOs which ... the country. The number of mental health disorders in South ... ,The State spending towards mental health has risen by ...
... a research headed by Dr Michael Fenech studied the damage of ... study stated that excess intake of // alcoholic beverages resulted in ... the course of the study, six men aged 21-26 stuck to ... drank 300 millilitres of either complete red wine, red wine with ...
Cached Medicine News:Health News:NY Health Dept Bans 3 Ayurveda Drugs 2Health News:The Looming Controversy Surrounding Facial Transplant 2
... S. typhi rapid test is a ... test employs a conation of monoclonal,antibody/colloidal ... antibody immobilized on the solid phase. ... associated Salmonella typhi (typhoid) infection with ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
For the rapid determination of human chorionic gonadotropin (hCG) in urine and serum. The test strip is used to obtain a visual qualitative result....
Medicine Products: